Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates

FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events